News & Press

Filter by year:

GeNeuro’s Temelimab Phase IIa Data in Type 1 Diabetes at 12 Months Confirms RAINBOW Positive Results

Geneva, Switzerland, 7 May 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that a six-month extension of its Phase IIa study of temelimab (GNbAC1) in T1D confirmed all previouslyobserved positive observations in the trial, meeting its primary objective. GeNeuro believes these data open the door to further development in early-onset T1D pediatric patient population.

GeNeuro: Cash position at 31 March 2019 and Business Review

Geneva, Switzerland, April 24, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today reported on its 2019 first quarter cash position and issued a business update.

GeNeuro Reports 2018 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 1, 2019 –  GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and Type-1 Diabetes (T1D), today reported its full-year results for the year ended December 31, 2018 and provided a corporate update.

GeNeuro’s ANGEL-MS Phase 2b extension study confirms and extends the neuroprotective effects of temelimab in MS

Geneva, Switzerland, 12 March 2019 – 07:00am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), type-1 diabetes (T1D) and amyotrophic lateral sclerosis (ALS), today announced positive results from the ANGEL-MS study of its lead product, temelimab in MS. Temelimab is a humanized, monoclonal antibody designed to neutralize pHERV-W, a pathogenic protein thought to be a causal factor in the development of multiple sclerosis.

GeNeuro: Cash position at 31 December 2018 and Business Review

Geneva, Switzerland, 29 January 2019 – 6:00pm CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, announced its cash position at 31 December 2018 and provides an updated review of its clinical developments.

La Web TV à la rencontre des dirigeants au Biomed Event 2019

Interview diffusée sur la Web TV : www.labourseetlavie.com

GeNeuro Announces Positive Results from Temelimab (GNbAC1) Phase 1 High-dose Clinical Trial

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes, today announced positive safety and tolerability results from a Phase 1 study assessing the administration of high doses of temelimab (GNbAC1) to treat MS and other auto-immune diseases.

 

 


Results 1-7 of 7